(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
Parents search for children missing since a volcanic eruption in Colombia 40 years ago- 5 Wellbeing Applications Assist You With remaining Fit
- CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation
- Figure out How to Pick the Right Dental specialist for Your Dental Inserts
- IDF strikes Hamas terror cell operating near Israeli troops in northern Gaza
- The Iconic, Instantly Recognizable Plastic Chair That's Known All Around The World
- Building an Individual Brand: Illustrations from Powerhouses
- What happened to Eleven after the ambiguous 'Stranger Things' series finale? Millie Bobby Brown knows — but 'swore herself to secrecy'
- It Looks Like a Tiny, Fluffy Dragon, But It's Really a Bird. Meet the Great Eared Nightjar
